Current situation with the development of the endocrine disruption criteria 13 March 2014 Markus Griesser (BASF SE) Chair ECPA ED Expert Group.

Slides:



Advertisements
Similar presentations
EPAA Annual Conference Regulatory acceptance and implementation of 3Rs approaches Plant protection products Patricia Brunko European Commission - DG SANCO.
Advertisements

Introduction to Article 45 (5) of the CLP Regulation
Research and Innovation Summary of MS questions on the Commission's proposal for DG Research & Innovation Research and Innovation Rules for Participation.
Karin Nienstedt - DG SANTE / E3
ECPA view on the implementation and the adaptation of Regulation 1107/2009 ECPA ECCA Conference Brussels March 2015 Dr. Martyn Griffiths, Bayer SAS.
1 INTRODUCTION What is Happening with REACH Hong Kong
1. European Commission Status GHS Implementation in the European Community Global Thematic Workshop on Strengthening Capacities to Implement the GHS Johannesburg.
Health and Safety Executive Regulator’s expectation in implementation of comparative assessment Jayne Wilder Chemicals Regulation Directorate, Health and.
Cut-Offs and Candidates for Substitution:
Health and Consumers Health and Consumers Reviewing the implementation of Regulation (EC) No 1107/2009 Crop Protection European Regulatory Conference
Toxics Use Reduction Institute Chemicals Policy in Europe: New Directions Rachel Massey Policy Analyst April 2006.
Health and Consumers Health and Consumers ECPA/ECCA Regulatory conference on March 2014 Developments in the area of pesticide residues – Commission.
Chemicals Management in a Transatlantic Perspective Henrik Selin November 10, 2008.
Decision making for AIR active substances
Health and Safety Executive Health and Safety Executive Improving the efficiency of the regulatory process Rob Mason Head of Regulatory Policy Chemicals.
Nano-Safety: Some Future Perspectives Conference on Nano-Safety April, Slovenia, Ljubljana Bjorn G. Hansen dHoU Chemicals, DG ENV, European Commission.
State of the Science of Endocrine Disrupting Chemicals – 2012 UNEP and WHO published in February, 2013 From ”Global Assement of EDCs” published 2002 to.
STATE OF THE ART AND PERSPECTIVES IN MEDICAL DEVICE LEGISLATION 3rd National Conference on Medical devices Roma, 13th April 2010 Sabine Lecrenier Head.
Mike Murray Chair of EFPIA EH&S AHG MPA Conference Uppsala
European Commission Further Impact Assessment of REACH ETUC Conference Brussels, 11 February 2005 Patrick Hennessy DG Enterprise and Industry.
June 2008 Proposal for a Regulation to replace Directive 91/414/EEC July 2008 T Lyall.
Food safety – an introduction Lecture 35 Economics of Food Markets Alan Matthews.
Development and application of guidance documents – industry view Dr Martin Schaefer ECCA-ECPA Conference March 2014.
Animal Welfare EU Strategy Introduction Community Action Plan The Commission's commitment to EU citizens, stakeholders, the EP and.
Introduction to the GHS: An overview for Comprehensibility Testing UNITAR-CWM Date: Location:
Support for the Modernisation of the Mongolian Standardisation system – EuropeAid/134305/C/SER/MN Training on standardisation Support to the Modernisation.
Quill Law Group LLC1 EDSP Compliance Timing, Procedural and Legal Issues Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Briefing by Department of Health to joint meeting of the Portfolio Committees on Agriculture, Forestry and Fisheries, Health, Trade and Industry, Rural.
1 REACH, the Future EU policy for Chemicals European Conference in Eretria April 27, 2004 Tony Musu – European Trade Union Technical Bureau/ETUC.
Advisory group on fruit and vegetables 7 March 2008
Review of veterinary medicines legislation in 2010 Mario Nagtzaam Unit F2 „Pharmaceuticals“ Directorate-General Enterprise and Industry European Commission.
Which information identifies a chemical as endocrine disrupting? Poul Bjerregaard Institute of Biology University of Southern Denmark Odense and Danish.
Recommendation 2001/331/EC: Review and relation to sectoral inspection requirements Miroslav Angelov European Commission DG Environment, Unit A 1 Enforcement,
UNEP’s project on Endocrine Disrupting Chemical (EDCs) for 2015–2019: Provision of Information on EDCs Geneva, 25 September2015 Third Meeting of the EDC.
The Growing Impact of EU Legislation
Health and Consumers Health and Consumers Commission view on the implementation of Regulation (EC) No 1107/2009 ECPA/ECCA Brussels Regulatory Conference.
Science Symposium, 26 May 2014, New Delhi, India Dr Gerald Renner Director Technical Regulatory Affairs Cosmetics Europe EU scenario on alternatives in.
Land Use, Land Use Change and Forestry (LULUCF) European Commission expert group on forest fires Antalya, 26 April 2012 Ernst Schulte, DG ENV on behalf.
EDSP Implementation: Concerns for the Pesticide Industry ISRTP 2009 Endocrine Workshop: The Endocrine Disruptor Screening Program: What Can Screening Results.
1 State of Play Prioritisation of Substances By modelling Hazard & Exposure Klaus Daginnus Institute for Health & Consumer Protection Joint Research Centre,
June 2009 Regulation on pesticide statistics Pierre NADIN ESTAT E1- Farms, agro-environment and rural development
Health and Food Safety EU strategy for Pharmaceuticals in the Environment Patrizia Tosetti DG SANTE European Commission China/EU Pharmaceutical Industry.
Purpose, Scope and Application of the GHS 1. The Globally Harmonized System of Classification and Labeling of Chemicals (GHS) is a rational and comprehensive.
Abstract A step-wise or ‘tiered’ approach has been used as a rational procedure to conduct environmental risk assessments in many disciplines. The Technical.
Introduction to REACH Flavie Guérin U.S. Mission to the EU 15 November 2011.
Leader Axis Rural Development Policy by Jean-Michel Courades AGRI-F3.
IADSA Scientific Forum 2009 The scientific substantiation of health claims David P. Richardson Scientific Adviser to UK Council for Responsible Nutrition.
1 Package on food improvement agents Food additives Food enzymes Flavourings Common procedure Developments since earlier consultation.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
EFSA Trusted science for safe food Guilhem de Sèze
How to build a non-toxic environment strategy for the EU
Business environment in the EU Prepared by Dr. Endre Domonkos (PhD)
DG Environment, Unit D.2 Marine Environment and Water Industry
Principles and Key Issues
Update on recent developments in the ed regulatory landscape in Europe
Reprotoxic substances in the context of the revision of the 2004/37/EC (CMD) - Viewpoint from WPC and France - Matthieu Lassus Ministry of Labour, Employment,
IV Encuentro de la almendra y la avellana Reus 24 de abril 2018
State of the Science of Endocrine Disrupting Chemicals – 2012
Animal Welfare EU Strategy
State of play endocrine disruptors
State of play in the EU for criteria to identify endocrine disruptors
Review of Annexes I and II of the Groundwater Directive 2006/118/EC
Revision of the technical annexes of the BPR
Conclusions from the Review of REACH
EUnetHTA Assembly May 2018.
Revision of Decision 2010/477/EU
DG Environment, Unit D.2 Marine Environment and Water Industry
Update on EU draft Regulation
DG Environment, Unit D.2 Marine Environment and Water Industry
Presentation transcript:

Current situation with the development of the endocrine disruption criteria 13 March 2014 Markus Griesser (BASF SE) Chair ECPA ED Expert Group

Outline Introduction Proposals for ED criteria and further scientific input State of play and way forward Potential impact on agriculture, innovation and trade Summary

Definition WHO/IPCS (2002) „An endocrine disruptor is an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse effects in an intact organism, or ist progeny, or (sub)populations.“ Widely accepted definition, but… The WHO definition is not a regulatory definition!

What is the concern about? WHO/ UNEP report 2012 –Many ED-related diseases are on the rise –Human and wildlife populations are exposed to EDCs –Numerous laboratory studies support the idea that chemical exposures contribute to endocrine disorders –Internationally agreed and validated test methods capture only a limited range of the known spectrum of ED effects The 2012 report raises a global concern on EDCs

Critique of the WHO report Critical review by Jim Lamb et al (February 2014) –Summary is not a true representation of the main report –Disease trends are attributed to ED without evidence of their causes or discussion of other possible factors –Dose-response and potency are addressed poorly The report does not provide a balanced perspective and is not an accurate reflection of the state of the science on endocrine disrupters

Horizontal ED criteria for all sectors Pesticides Hazard-based cut-off Limited derogations possible ED criteria: proposal by December 2013 Biocides Hazard-based cut-off Derogations possible ED criteria: adoption by December 2013 REACH ED may be SVHC Authorisation based on risk assessment ED criteria: no legal requirements 6 ED regulation in the EU Harmonized criteria, but consequences differ

Regulation 1107/2009 Annex II, Article (Human Health) –“An active substance, safener or synergist shall only be approved if …. it is not considered to have endocrine disrupting properties that may cause adverse effect in humans, unless the exposure … is negligible, that is, the product is used in closed systems or in other conditions excluding contact with humans and where residues of the active substance, safener or synergist concerned on food and feed do not exceed the default value set in accordance with … Regulation (EC) No 396/2005.” Annex II, Article (Environment) –“An active substance, safener or synergist shall only be approved if … it is not considered to have endocrine disrupting properties that may cause adverse effects on non-target organisms unless the exposure of non-target organisms … is negligible.” ED in EU pesticides legislation No criteria defined despite legislative deadline

Interim criteria Pending the adoption of these criteria, substances that are or have to be classified, in accordance with the provisions of Regulation (EC) No 1272/2008, as carcinogenic category 2 and toxic for reproduction category 2, shall be considered to have endocrine disrupting properties. –Interim criteria not scientifically justified (not all substances classified as C2 and R2 are automatically endocrine disrupters) –No interim criteria and legislative deadline for the environment –Interim criteria are beeing applied for the CfS list –Some member states want to apply interim criteria for AIR2 –ECPA position: interim criteria should not be applied for regulatory decision making ED in EU pesticides legislation Provision is a poor substitute for scientific criteria

Outline Introduction Proposals for ED criteria and further scientific input State of play and way forward Potential impact on agriculture, innovation and trade Summary

First detailed proposal for ED criteria Original work published in 2009 as technical report Detailed assessment scheme to identify EDs of regulatory concern for human health and wildlife In 2013, the American Society of Toxicology (SOT) awarded it “Best Published Paper Advancing the Science of Risk Assessment” Industry proposal to regulate ED Industry plays a proactive and constructive role Source:R. Bars et al. Regulatory Toxicology and Pharmacology 64 (2012), 143–154

BfR/ CRD proposal (human health) Source: JOINT DE – UK POSITION PAPER. REGULATORY DEFINITION OF AN ENDOCRINE DISRUPTER IN RELATION TO POTENTIAL THREAT TO HUMAN HEALTH. May 2011.

Category 1: Confirmed ED -Adverse in vivo effects & ED MoA highly plausible -ED MoA in vivo clearly linked to adverse effects in vivo (e.g. by read across) Category 2a: Suspected ED -Some evidence, mainly based on in vivo data Category 2b: Indicated ED -Some in vitro/ in silico evidence indicating an ED potential DK EPA proposal

Members -Experts from member states authorities, industry and NGOs -EU agencies (EFSA, ECHA) & COM services as observers -Chaired by the Joint Research Centre (JRC) Final Report -Hazard identification: Consideration of mode of action and adversity in parallel applying weight of evidence -Human health: Potency, severity, irreversibility and lead toxicity are relevant for hazard characterization -Environment: Adverse effects must be population relevant Expert Advisory Group (EAG)

Joint work with experts from EMA, ECHA, EEA Mandate by COM, published in March Reasonably complete set of standardised assays for EATS in mammals and fish are available -Critical effect, severity, (ir)reversibility and potency are part of hazard characterization of EDs -Mixture toxicity and low-dose effects are not unique for EDs -Risk assessment makes best use of available information EFSA Scientific Opinion EDs can be treated like most other substances of concern for human health and environment

Presented to the ED Ad hoc meeting (Feb. 2013) Category 1: Endocrine Disruptors -Evidence mainly based in vivo data Category 2: Suspected EDs -Less evidence than Cat 1 (incl. in vitro and in silico data) ECPA has severe concerns with the proposal -Categorization scheme (not required by any EU legislation) -Category 1 goes beyond the WHO definition -Focus on hazard identification -Elements of hazard characterization not considered (e.g. potency, severity of effects, irreversibilty) Proposal by DG Environment

The criteria should… -be based on the widely accepted WHO definition -include elements of hazard characterization (e.g. potency, severity, lead toxic effect, irreversibility) -be a single set of criteria as required by the legislation (and not a categorization) Industry view on the ED criteria Hazard idenfication (WHO definition; adverse effect and ED MoA) Hazard characterization Exposure characterization Risk assessment DG Envi proposal Some MS US EPA, Industry

Outline Introduction Proposals for ED criteria and further scientific input State of play and way forward Potential impact on agriculture, innovation and trade Summary and conclusions

State of play and way forward Anticipated timelines DG Envi to develop horizontal ED criteria Impact assessment process ? public consultationroadmap COM to review REACH (thresholds for ED) Election EPNew COM DG Sanco drafting pesticides criteria DG Envi drafting biocides criteria ? ? 2016 DG Envi work on ED strategy ? ED strategy and criteria should be „one package“

Outline Introduction Proposals for ED criteria and further scientific input State of play and way forward Potential impact on agriculture, innovation and trade Summary

Scope Based on the proposal by DG Environment (February 2013) Impact on agriculture, trade and future innovation Key messages – % of the European crop protection market will be affected (3 – 4 billion €) –Fungicides are particularly vulnerable: The ten most important cereal fungicides in Germany would be lost, in France 7 out of the top 10 products would be removed –Yield losses on key crops would be % in an average year and up to 50 % in years of high disease pressure –Significant impact on innovation and international trade ECPA impact assessment Impact has to be considered in drafting the criteria

CategoryTox Assessment (98 substances) Ecotox Assessment (20 substsances) ED more likely to pose a risk 5 %35 % ED less likely to pose a risk9 %5 % Potential EDs requiring further information 26 %55 % Not considered ED59 %5 % CRD impact assessment (I) Based on the BfR/ CRD proposal (human health) and the CRD proposal (environment) The Proposal by DG Environment would have an even higher impact

Prepared by the Food and Environment Research Agency (fera) Agronomic and economic impact –Loss of „Category 1“: 225 Mio GBP (260 Mio €) –Loss of „Category 1 & 2“ : 440 Mio GBP (510 Mio €) Based on the assumption that all other ais remain available (which is unrealistic) Production of many crops will not be viable anymore in the UK (e.g. lettuce, soft fruit) CRD impact assessment (II) Actual impact is likely to be underestimated

Source: R&D trends for chemical crop protection products and the position of the European Market. A consultancy study undertaken for ECPA. Phillips McDougall, September 2013 Impact on innovation Current situation in the EU Active ingredients in development (worldwide) Share of active ingredients introduced or in development ED criteria have the potential to further hinder innovation and research in the EU

Based on the assumption that all MRLs will be set at the default value of 0.01 mg/kg Imports worth 65 billion € would be affected by ED cut-off criteria alone Impact on international trade 8.4 billion € 7.9 billion € 6.9 billion € 24.3 billion € Source: Potential Trade Effects on World Agricultural Exporters of European Union Regulations on Endocrine Disruptors. Prepared by Kyd D. Brenner LLC for CropLife International, February Huge potential impact on international trade

ECPA welcomes the impact assessment, but is concerned about the significant delays ECPA view on the impact assessment -Impacts on sectors should be assessed separately -All existing impact assessments should be considered -Assessment should be robust and detailed enough to provide a meaningful conclusion -Intended and unintended impacts should be considered: agronomic impacts, impacts on human health and environment, socio-economic impacts, trade impacts and global competitiveness of European agriculture -Assessment should consider a risk assessment option Commission impact assessment

Outline Introduction Proposals for ED criteria and further scientific input State of play and way forward Potential impact on agriculture, innovation and trade Summary

ECPA takes ED-related concerns seriously and believes that they can be addressed using a science and risk-based approach The WHO definition and elements of hazard cha- racterization should be the basis for the criteria DG Environments‘s proposal would have had a significant negative impact on European agriculture, innovation and international trade The Commission impact assessment offers the chance to provide a more solid basis for the ED criteria and the revision of the ED strategy Summary

THANK YOU FOR YOUR ATTENTION